Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.54 |
| ▸ | PARP1 | P09874 | 6/20 | 0.50 |
| ▸ | PARP10 | Q53GL7 | 15/20 | 0.49 |
| ▸ | PARP11 | Q9NR21 | 14/20 | 0.49 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.42 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.42 |
| ▸ | TIPARP | Q7Z3E1 | 1/20 | 0.42 |
| ▸ | PARP16 | Q8N5Y8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31012419 | 1.00 | ACHE (0.54) | ACHEPARP1PARP10PARP11PARP15 | |
| SCHEMBL14842620 | 0.80 | ACHE (0.54) | ACHEPARP1PARP10PARP11 | |
| SCHEMBL30466437 | 0.77 | PARP10 (0.42) | ACHEPARP1PARP10PARP11 | |
| SCHEMBL24136591 | 0.77 | PARP10 (0.42) | ACHEPARP1PARP10PARP11 | |
| SCHEMBL30466416 | 0.72 | ACHE (0.43) | ACHEPARP1PARP10PARP11 | |
| SCHEMBL24136677 | 0.72 | ACHE (0.43) | ACHEPARP1PARP10PARP11 | |
| SCHEMBL10129821 | 0.70 | ACHE (0.50) | ACHEPARP1PARP10PARP11 | |
| SCHEMBL30402278 | 0.70 | ACHE (0.50) | ACHEPARP1PARP10PARP11 | |
| SCHEMBL24136646 | 0.69 | KDM4E (0.56) | ACHEPARP1PARP10PARP11 | |
| SCHEMBL29600821 | 0.69 | KDM4E (0.56) | ACHEPARP1PARP10PARP11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220135582-A1 | NOVEL HETEROTRICYCLIC DERIVATIVE COMPOUND AND USE OF SAME | HANMI PHARMACEUTICAL CO., LTD. (KR) | 2022-05-05 | — | — | US | disclosed |
| EP-3929199-A1 | NOVEL HETEROTRICYCLIC DERIVATIVE COMPOUND AND USE OF SAME | Hanmi Pharmaceutical Co., Ltd. (KR) | 2021-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135582-A1 | NOVEL HETEROTRICYCLIC DERIVATIVE COMPOUND AND USE OF SAME | EZH2, EZH1, BMI1 | ACHE 4227/4885PARP1 1497/4885PARP10 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.